Literature DB >> 32723429

Recombinant subtype A and B human respiratory syncytial virus clinical isolates co-infect the respiratory tract of cotton rats.

Linda J Rennick1,2,3, Sham Nambulli1,2,3, Ken Lemon4, Grace Y Olinger2, Nicholas A Crossland2, Emma L Millar4, W Paul Duprex3,2,1.   

Abstract

Human respiratory syncytial virus (HRSV) is an important respiratory pathogen causing a spectrum of illness, from common cold-like symptoms, to bronchiolitis and pneumonia requiring hospitalization in infants, the immunocompromised and the elderly. HRSV exists as two antigenic subtypes, A and B, which typically cycle biannually in separate seasons. There are many unresolved questions in HRSV biology regarding the interactions and interplay of the two subtypes. Therefore, we generated a reverse genetics system for a subtype A HRSV from the 2011 season (A11) to complement our existing subtype B reverse genetics system. We obtained the sequence (HRSVA11) directly from an unpassaged clinical sample and generated the recombinant (r) HRSVA11. A version of the virus expressing enhanced green fluorescent protein (EGFP) from an additional transcription unit in the fifth (5) position of the genome, rHRSVA11EGFP(5), was also generated. rHRSVA11 and rHRSVA11EGFP(5) grew comparably in cell culture. To facilitate animal co-infection studies, we derivatized our subtype B clinical isolate using reverse genetics toexpress the red fluorescent protein (dTom)-expressing rHRSVB05dTom(5). These viruses were then used to study simultaneous in vivo co-infection of the respiratory tract. Following intranasal infection, both rHRSVA11EGFP(5) and rHRSVB05dTom(5) infected cotton rats targeting the same cell populations and demonstrating that co-infection occurs in vivo. The implications of this finding on viral evolution are important since it shows that inter-subtype cooperativity and/or competition is feasible in vivo during the natural course of the infection.

Entities:  

Keywords:  HRSV; Pathogenesis; clinical isolates; cotton rat; respiratory system; subtype A/B

Year:  2020        PMID: 32723429     DOI: 10.1099/jgv.0.001471

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  3 in total

1.  Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants.

Authors:  Wendy K Jo; Alina Schadenhofer; Andre Habierski; Franziska K Kaiser; Giulietta Saletti; Tina Ganzenmueller; Elias Hage; Sibylle Haid; Thomas Pietschmann; Gesine Hansen; Thomas F Schulz; Guus F Rimmelzwaan; Albert D M E Osterhaus; Martin Ludlow
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

2.  Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures.

Authors:  L C Rijsbergen; M M Lamers; A D Comvalius; R W Koutstaal; D Schipper; W P Duprex; B L Haagmans; R D de Vries; R L de Swart
Journal:  mSphere       Date:  2021-05-12       Impact factor: 4.389

3.  CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats.

Authors:  Gia Green; Sara M Johnson; Heather Costello; Kelsey Brakel; Olivia Harder; Antonius G Oomens; Mark E Peeples; Hong M Moulton; Stefan Niewiesk
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.